FDA Grants Accelerated Approval to Immunomedics for Trodelvy in Breast Cancer Patients

On April 22, Immunomedics, Inc. (IMMU) announced that they received accelerated FDA approval of Trodelvy™ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC). The treatment is specifically for patents who have received at least two prior therapies for metastatic disease. This is a particularly aggressive form of cancer for which there are few effective therapies, so this approval gives doctors a novel tool for treating patients with this disease. Immunomedics is a leading biopharmaceutical company specializing in the area of antibody-drug conjugates (ADC).


Sonal detected the event and issued an alert at 11:47 am. The last trade had been at 10:47 am for $21.97. The stock price immediately rose above $28 following the news release before pulling back towards the closing. Immunomedics’ stock, however, continued to rise over the next three trading sessions. The stock closed at $29.06 on April 28 for a gain of 32%.

If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!